A single dose,four way,crossover,open label to evalauate the bioavailability of novel formulation of Abiraterone acetate versus the originator Abiraterone acetate formulation in under fasted conditions in healthy male subjects

Trial Profile

A single dose,four way,crossover,open label to evalauate the bioavailability of novel formulation of Abiraterone acetate versus the originator Abiraterone acetate formulation in under fasted conditions in healthy male subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 25 May 2017

At a glance

  • Drugs Abiraterone acetate (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms Study 102
  • Most Recent Events

    • 25 May 2017 Results published in the Internet Document
    • 31 Mar 2017 New trial record
    • 18 Feb 2017 Results presented at the 2017 Genitourinary Cancers Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top